Electrofisiología cardiaca y arritmias

Singh, 2007, Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter, N Engl J Med, 357, 987, 10.1056/NEJMoa054686 Kober, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456 Hohnloser, 2009, Effect of dronedarone on cardiovascular events in atrial fibrillation, N Engl J Med, 360, 668, 10.1056/NEJMoa0803778 Disertori, 2009, Valsartan for prevention of recurrent atrial fibrillation, N Engl J Med, 360, 1606, 10.1056/NEJMoa0805710 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Connolly, 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, 367, 1903, 10.1016/S0140-6736(06)68845-4 Connolly, 2009, Effect of clopidogrel added to aspirin in patients with atrial fibrillation, N Engl J Med, 360, 2066, 10.1056/NEJMoa0901301 Huang, 2009, Role of signal-averaged electrocardiograms in arrhythmic risk stratification of patients with Brugada syndrome: a prospective study, Heart Rhythm, 6, 1156, 10.1016/j.hrthm.2009.05.007 Samani, 2009, A novel SCN5A mutation V1340I in Brugada syndrome augmenting arrhythmias during febrile illness, Heart Rhythm, 6, 1318, 10.1016/j.hrthm.2009.05.016 Benito, 2008, Gender differences in clinical manifestations of Brugada syndrome, J Am Coll Cardiol, 52, 1567, 10.1016/j.jacc.2008.07.052 Postema, 2009, Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org), Heart Rhythm, 6, 1335, 10.1016/j.hrthm.2009.07.002 Vincent, 2009, High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QTprolonging drugs to the occurrence of beta-blocker treatment “failures”, Circulation, 119, 215, 10.1161/CIRCULATIONAHA.108.772533 Hayashi, 2009, Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia, Circulation, 119, 2426, 10.1161/CIRCULATIONAHA.108.829267 Atienza, 2009, Real-time dominant frequency mapping and ablation of dominant frequency sites in atrial fibrillation with left-to-right frequency gradients predicts long-term maintenance of sinus rhythm, Heart Rhythm, 6, 33, 10.1016/j.hrthm.2008.10.024 Calkins, 2009, Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses, Circ Arrhythmia Electrophysiol, 2, 349, 10.1161/CIRCEP.108.824789 Cappato, 2009, Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation, J Am Coll Cardiol, 53, 1798, 10.1016/j.jacc.2009.02.022 Khan, 2008, Pulmonary-vein isolation for atrial fibrillation in patients with heart failure, N Engl J Med, 359, 1778, 10.1056/NEJMoa0708234 Kriatselis, 2009, A new approach for contrast-enhanced X-ray imaging of the left atrium and pulmonary veins for atrial fibrillation ablation: rotational angiography during adenosine-induced asystole, Europace, 11, 35, 10.1093/europace/eun311 Mansour, 2008, Initial experience with the Mesh catheter for pulmonary vein isolation in patients with paroxysmal atrial fibrillation, Heart Rhythm, 5, 1510, 10.1016/j.hrthm.2008.08.024 Boersma, 2008, Pulmonary vein isolation by duty-cycled bipolar and unipolar radiofrequency energy with a multielectrode ablation catheter, Heart Rhythm, 5, 1635, 10.1016/j.hrthm.2008.08.037 Neumann, 2008, Circumferential pulmonary vein isolation with the cryoballoon technique results from a prospective 3-center study, J Am Coll Cardiol, 52, 273, 10.1016/j.jacc.2008.04.021 Sohara, 2009, Feasibility of the radiofrequency hot balloon catheter for isolation of the posterior left atrium and pulmonary veins for the treatment of atrial fibrillation, Circ Arrhythmia Electrophysiol, 2, 225, 10.1161/CIRCEP.108.817205 Holmes, 2009, Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial, Lancet, 374, 534, 10.1016/S0140-6736(09)61343-X Gold, 2008, Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy, Circulation, 118, 2022, 10.1161/CIRCULATIONAHA.107.748962 Chow, 2008, J Am Coll Cardiol, 52, 1607, 10.1016/j.jacc.2008.08.018 Arias, 2008, A single implantable cardioverterdefibrillator shock unmasking an electrical storm of 389 ventricular tachycardia episodes triggering device therapies, Am J Emerg Med, 26, 10.1016/j.ajem.2008.03.006 Arias, 2008, Reducción de descargas del desfibrilador mediante estimulación antitaquicárdica durante la carga, Rev Esp Cardiol, 61, 1087, 10.1157/13126048 Cabrera, 2005, Seguimiento a largo plazo tras la ablación con radiofrecuencia de taquicardias ventriculares en pacientes portadores de un desfibrilador automático implantable, Rev Esp Cardiol, 58, 491, 10.1157/13074843 Bogun, 2009, Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate, J Am Coll Cardiol, 53, 1138, 10.1016/j.jacc.2008.11.052 Codreanu, 2008, Electroanatomic characterization of post-infarct scars comparison with 3-dimensional myocardial scar reconstruction based on magnetic resonance imaging, J Am Coll Cardiol, 52, 839, 10.1016/j.jacc.2008.05.038 Cano, 2009, Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left ventricular nonischemic cardiomyopathy, J Am Coll Cardiol, 54, 799, 10.1016/j.jacc.2009.05.032 García, 2009, Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia, Circulation, 120, 366, 10.1161/CIRCULATIONAHA.108.834903 Aliot, 2009, Europace, 11, 771, 10.1093/europace/eup098 Sánchez Muñoz, 2009, Análisis espectral de la fibrilación ventricular sostenida y no sostenida en portadores de desfibrilador implantable, Rev Esp Cardiol, 62, 690, 10.1016/S0300-8932(09)71337-5 Haissaguerre, 2002, Mapping and ablation of idiopathic ventricular fibrillation, Circulation, 106, 962, 10.1161/01.CIR.0000027564.55739.B1 Knecht, 2009, Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study, J Am Coll Cardiol, 54, 522, 10.1016/j.jacc.2009.03.065 Haissaguerre, 2008, Sudden cardiac arrest associated with early repolarization, N Engl J Med, 358, 2016, 10.1056/NEJMoa071968 Viskin, 2009, Idiopathic ventricular fibrillation “Le Syndrome d’Haissaguerre” and the fear of J waves, J Am Coll Cardiol, 53, 620, 10.1016/j.jacc.2008.11.011 Haissaguerre, 2009, Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy, J Am Coll Cardiol, 53, 612, 10.1016/j.jacc.2008.10.044 Peinado, 2008, Registro Español de Desfibrilador Automático Implantable. IV Informe Oficial del Grupo de Trabajo de Desfibrilador Automático Implantable de la Sociedad Española de Cardiología (2007), Rev Esp Cardiol, 61, 1191, 10.1157/13127850 Poole, 2008, Prognostic importance of defibrillator shocks in patients with heart failure, N Engl J Med, 359, 1009, 10.1056/NEJMoa071098 Mark, 2008, Quality of life with defibrillator therapy or amiodarone in heart failure, N Engl J Med, 359, 999, 10.1056/NEJMoa0706719 Cygankiewicz, 2009, Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverterdefibrillators, Heart Rhythm, 6, 468, 10.1016/j.hrthm.2008.12.023 Levy, 2009, Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population, Circulation, 120, 835, 10.1161/CIRCULATIONAHA.108.816884 Wilkoff, 2009, The DAVID (Dual Chamber and VVI Implantable Defibrillator) II trial, J Am Coll Cardiol, 53, 872, 10.1016/j.jacc.2008.10.057 Wilkoff, 2002, Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial, JAMA, 288, 3115, 10.1001/jama.288.24.3115 Beshai, 2007, Cardiac-resynchronization therapy in heart failure with narrow QRS complexes, N Engl J Med, 357, 2461, 10.1056/NEJMoa0706695 Linde, 2008, Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms, J Am Coll Cardiol, 52, 1834, 10.1016/j.jacc.2008.08.027 Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 [en prensa]. Bai, 2008, Mortality of heart failure patients after cardiac resynchronization therapy: identification of predictors, J Cardiovasc Electrophysiol, 19, 1259, 10.1111/j.1540-8167.2008.01234.x Swerdlow, 2008, Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrillator leads, Circulation, 118, 2122, 10.1161/CIRCULATIONAHA.108.796136 Arias, 2009, The Sprint Fidelis implantable cardioverter-defibrillator (ICD) leads (Medtronic, Inc., Minneapolis, MN, USA) were removed from the market in October 2007 because of the rate of pace-sense conductor fractures, Heart Rhythm, 6, e6, 10.1016/j.hrthm.2008.11.027 Hauser, 2009, Increasing hazard of Sprint Fidelis implantable cardioverter-defibrillator lead failure, Heart Rhythm, 6, 605, 10.1016/j.hrthm.2009.02.024